医学交流课件：MarshallICD Update.China Evera Launch Meeting

1、ICD Update Marshall Stanton, M.D. Vice President and General Manager, ICD Business Medtronic Medtronic confidential. Do not share or distribute. Evera and Quattro: The new standard for ICD systems Its peace of mind. Quattro, the most reliable lead; 96% 10 years It lasts longer. VR: 11 yrs., DR: 9 yr

2、s. With unsurpassed longevity Its smart. SmartShock, 98% inappropriate shock free 1 year Its contoured. With PhysioCurve Design; 30% decreased pressure 3 | MDT Confidential. Internal use only. SmartShock: PainFree SST Clinical Study Showed Very Low Rates of Inappropriate Shocks Dual Chamber and CRT

3、ICDs: 98.5% Inappropriate Shock Free at 1 Year Single Chamber ICDs: 97.5% Inappropriate Shock Free at 1Year Auricchio, et al. Heart Rhythm. 2015 in press. 4 | MDT Confidential and Proprietary; Do Not Copy or Distribute Evera MRI: Extend the Evera platform to address the need for MRI Proven Safety Ex

4、tensive, robust and exclusive MRI testing and modeling Supported by the most clinical MRI evidence and experience Uses Quattro, the industrys best ICD lead Full MRI Access Clinical Efficiency No anatomical exclusions No restrictions on the number or duration of the MRI scans No limitation on patient

5、 position in the MRI scan No need to track the duration or number of MRIs Clear and complete MR conditions for use 5 | MDT Confidential and Proprietary; Do Not Copy or Distribute Visia AF Do Not Copy or Distribute AIGISRX R Fully Resorbable Envelope The ONLY antibacterial device available for CIED*

6、surgical implants Combination of minocycline and rifampin shown to reduce infection.2-6 Published data shows infection rate reduced 70-90% * CIED = cardiac implantable electronic devices 7 | MDT Confidential and Proprietary; Do Not Copy or Distribute TYRX Envelope Benefit vs. Single Agent Therapy Pa

7、thogens Responsible for CIED InfectionsSingle Agent Therapy1AIGSRx and AIGISRx R1-4 Cefazolinvancomycinminocycline and rifampin Coagulase (-) Staphylococcus (eg. S. epidermidis) Methicillin-sensitive S. aureus (MSSA) Methicillin-resistant S. aureus (MRSA) Escherichia coli Haemophilus influenzae M. catarrhalis Corynebacterium jeikeium 8 | MDT Confidential and Proprietary; Do Not Copy or Distribute AIGISRX R Fully Resorbable Envelope Time sequence demonstrating bioresorbability of AIGISRX R after 9 weeks AIGISRX R at 4 weeks Envelope is dissolving into fragments AIGISRX R at 9 w